


MULTIMODAL **optomap**[®] ENHANCES THE MANAGEMENT OF AMD



optomap has helped re-define age-related macular degeneration (AMD) as a pan-retinal disorder finding 97% of eyes with the disease have peripheral retinal changes^{1,2}.

optomap images enable pole to periphery assessment in a high resolution, single capture facilitating the monitoring and measurement of geographic atrophy (GA) as well as evaluation of the retinal periphery.

- New imaging guidelines suggest autofluorescence (*af*) plays a key role in monitoring the progression of GA. When considering treatment color and *af* imaging are recommended at baseline. During treatment, bimonthly OCT is recommended to monitor for adverse events and *af* to confirm impact on growth reduction.
- Multimodal ultra-widefield (UWF[™]) **optomap** imaging has confirmed the presence of pan-retinal AMD-related pathologic changes including hard, crystalline, and soft drusen; retinal pigment epithelial changes; choroidal neovascularization (CNV) and atrophy evidenced by hypoautofluorescence and hyperautofluorescence in the peripheral retina^{1,2} in subjects with AMD, even in those without central sight-threatening macular disease.

“The results of the 10-year follow-up of AREDS2 participants demonstrate the extensive and relentless progression of the AMD lesions. The disease is not confined to the macula but extensive throughout the retinal and its periphery.”³


— IOVS, 2021

See how **optomap** will help you manage your patients. For more information call **800-854-3039** or email **BDS@optos.com**



CLINICAL SUMMARY

More findings regarding multimodal optomap enhances the management of AMD



- All Optos devices include *color* and *af* imaging to support the monitoring of AMD, for advanced management OCT, FA, ICG can be included in the same device.
- Age-related macular degeneration is best managed with multimodal imaging and may be more than a “macular” condition but one that involves the entire retina.²
- **optomap** is equivalent to traditional fundus photography for grading AMD and is better for imaging subjects who have media opacity. The laser based imaging provides a higher resolution image in terms of sharpness and contrast compared to white light images through media opacity.¹
- In the OPERA study, 484 subjects underwent **optomap color rg** and *af* imaging. Drusen were found in 97% of eyes in the mid-periphery and 77% of eyes in beyond the vortex vein ampullae. Super large drusen were found in 63% in the mid-periphery and 39% in the far periphery.²
- The results of the 10-year follow-on of AREDS2 participants demonstrate the extensive and relentless progression of the AMD lesions.³
- **optomap fa** demonstrated that 84.59% of AMD subjects had hyperfluorescent characteristics in which the main contributors were drusen, paving stone, and atrophic areas.⁴
- **optomap icg** captures significant peripheral changes in 80% of AMD patients.⁵
- OptosAdvance includes image annotations to measure:
 - GA area of atrophy
 - GA diameter of a region of interest
 - GA follow-up visit measurement
 - GA follow-up visit image overlay

Reference:

1. Lengyel et al. A Population-Based Ultra-Widefield Digital Image Grading Study for Age-Related Macular Degeneration-Like Lesions at the Peripheral Retina. *Ophthalmology*. 2015.
2. Chew et al. Peripheral Retinal Changes Associated with Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2. *Ophthalmology*. 2017.
3. Progression of Age-Related Macular Degeneration measured by Ultrawidefield Imaging in the Age-Related Eye Disease Study 2 10 Year Follow-On. *IOVS*. 2021.
4. Vatavuk et al. Morphological and Angiographic Peripheral Retinal Changes in Patients with Age-Related Macular Degeneration. *Ophthalmology Retina*. 2017.
5. Klufas. Feasibility and Clinical Utility of Ultra-Widefield Indocyanine Green Angiography. *Retina*. 2013.



Optos UK/Europe
+44 (0)1383 843350
ics@optos.com

Optos North America
800 854 3039
usinfo@optos.com

Optos DACH
DE: 0800 72 36 805
AT: 0800 24 48 86
CH: 0800 55 87 39
ics@optos.com

Optos Australia
+61 8 8444 6500
auinfo@optos.com

Contact us:

